Jawad Sheqwara, MD
Hematology & Oncology · Waycross, GANPI 1285881201
Payments from drug & device makers
Across 353 payments — averaging $3030.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$662K
- Amgen$104K
- Seagen Inc.$63K
- Regeneron$57K
- Astrazeneca UK Limited$56K
- AbbVie$40K
- plus $88K from 20 others
Across 1 payment — averaging $40,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acrotech Biopharma Inc.$40K
What the payments were for
- Consulting fees$31,16327%
- Speaking & faculty fees$66,28258%
- Travel & lodging$12,31211%
- Food & beverage$3,8293%
- Education$1670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 210 | $661,766 |
| Amgen | 3 | $104,210 |
| Seagen Inc. | 52 | $63,268 |
| Regeneron | 8 | $57,130 |
| Astrazeneca UK Limited | 2 | $55,620 |
| AbbVie | 2 | $40,050 |
| GSK | 6 | $28,849 |
| Pfizer | 15 | $13,841 |
| Genentech, Inc. | 2 | $10,859 |
| Ipsen Biopharmaceuticals, Inc | 8 | $8,733 |
| AstraZeneca | 8 | $6,443 |
| Incyte Corporation | 10 | $5,460 |
| Geron Corporation | 10 | $3,227 |
| Janssen Scientific Affairs, LLC | 3 | $2,480 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,373 |
| Novartis | 1 | $1,513 |
| Daiichi Sankyo Inc. | 2 | $1,010 |
| Karyopharm Therapeutics Inc. | 1 | $750 |
| Merck Kgaa | 1 | $690 |
| Beigene USA, Inc. | 1 | $675 |
| CTI Biopharma Corp. | 1 | $202 |
| ADC Therapeutics America, Inc. | 1 | $135 |
| TG Therapeutics, Inc. | 1 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $90 |
| Morphosys, US Inc. | 1 | $83 |
| Astellas Pharma US Inc | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,069,648 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 81 | $1,302,563 |
| PomalystPomalidomide | 38 | $843,240 |
| CalquenceAcalabrutinib Maleate | 25 | $375,625 |
| ImbruvicaIbrutinib | 20 | $337,426 |
| BrukinsaZanubrutinib | 26 | $307,102 |
| VenclextaVenetoclax | 30 | $260,550 |
| NinlaroIxazomib Citrate | 17 | $207,138 |
| PegasysPeginterferon Alfa-2a | 12 | $46,817 |
| EliquisApixaban | 22 | $13,868 |
| Acyclovir | 79 | $1,606 |
| Hydroxyurea | 24 | $647 |
| Dexamethasone | 45 | $465 |
| Prochlorperazine Maleate | 13 | $277 |
| Ondansetron OdtOndansetron | 18 | $212 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,373 | $843,24038 claims |
| AstraZenecaCalquence | $6,443 | $375,62525 claims |
| Beigene USA, Inc.Brukinsa | $675 | $307,10226 claims |
| AbbVieVenclexta | $40,050 | $260,55030 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $90 | $207,13817 claims |
| Genentech, Inc.Pegasys | $10,859 | $46,81712 claims |
| PfizerEliquis | $13,841 | $13,86822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Waycross
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.